Literature DB >> 20405248

Mechanism of action of immunomodulatory agents in multiple myeloma.

Thomas Reske1, Mariateresa Fulciniti, Nikhil C Munshi.   

Abstract

Immunomodulatory agents (IMiD's) have become an important drug category in the treatment of multiple myeloma. The agents have a complex mechanism of action that influence the microenvironment in the bone marrow. The microenvironment is an essential promotor of disease progression and therefore important in targeting the disease. The article reviews mechanism of action and essential pathways of IMiD's that are important in disease treatment.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20405248      PMCID： PMC3155938          DOI： 10.1007/s12032-010-9527-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  44 in total

1.  Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.

Authors:  D Gupta; S P Treon; Y Shima; T Hideshima; K Podar; Y T Tai; B Lin; S Lentzsch; F E Davies; D Chauhan; R L Schlossman; P Richardson; P Ralph; L Wu; F Payvandi; G Muller; D I Stirling; K C Anderson
Journal:  Leukemia       Date:  2001-12       Impact factor: 11.528

2.  A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB.

Authors:  Yi-Chu Lin; Chia-Tung Shun; Ming-Shiang Wu; Ching-Chow Chen
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

Review 3.  Molecular mechanisms of novel therapeutic approaches for multiple myeloma.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Nat Rev Cancer       Date:  2002-12       Impact factor: 60.716

4.  Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.

Authors:  Yu-Tzu Tai; Xian-Feng Li; Laurence Catley; Rory Coffey; Iris Breitkreutz; Jooeun Bae; Weihua Song; Klaus Podar; Teru Hideshima; Dharminder Chauhan; Robert Schlossman; Paul Richardson; Steven P Treon; Iqbal S Grewal; Nikhil C Munshi; Kenneth C Anderson
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

Review 5.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 6.  Thalidomide and lenalidomide: Mechanism-based potential drug combinations.

Authors:  Sonia Vallet; Antonio Palumbo; Noopur Raje; Mario Boccadoro; Kenneth C Anderson
Journal:  Leuk Lymphoma       Date:  2008-07

7.  Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.

Authors:  Masahiro Abe; Kenji Hiura; Shuji Ozaki; Shinsuke Kido; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

8.  Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.

Authors:  I Breitkreutz; M S Raab; S Vallet; T Hideshima; N Raje; C Mitsiades; D Chauhan; Y Okawa; N C Munshi; P G Richardson; K C Anderson
Journal:  Leukemia       Date:  2008-07-03       Impact factor: 11.528

Review 9.  Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.

Authors:  Constantine S Mitsiades; Nicholas S Mitsiades; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  J Cell Biochem       Date:  2007-07-01       Impact factor: 4.429

10.  Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

Authors:  K Dredge; J B Marriott; C D Macdonald; H-W Man; R Chen; G W Muller; D Stirling; A G Dalgleish
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640
View more
  7 in total

Review 1.  Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.

Authors:  Lesley J Scott; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

Review 2.  Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.

Authors:  Paul L McCormack
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

Review 3.  Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

4.  VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.

Authors:  Kalyan Nadiminti; Kamal Kant Singh Abbi; Sarah L Mott; Lindsay Dozeman; Annick Tricot; Allyson Schultz; Sonya Behrends; Fenghuang Zhan; Guido Tricot
Journal:  Onco Targets Ther       Date:  2017-01-06       Impact factor: 4.147

5.  [Clinical analysis of thalidomide in 36 untreated patients with T-cell lymphoma].

Authors:  H Y Huang; Y Q Song; W Zheng; X P Wang; Y Xie; N J Lin; M F Tu; C Zhang; L Y Ping; W P Liu; Z T Ying; L J Deng; N Ding; M Wu; Y L Sun; T T Du; X Leng; J Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-06-14

6.  Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis.

Authors:  Stephanie Lakritz; Peter A Forsberg; Daniel W Sherbenou; Tomer M Mark
Journal:  Clin Case Rep       Date:  2022-09-19

Review 7.  Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?

Authors:  Nishitha Thumallapally; Hana Yu; Divya Asti; Adarsh Vennepureddy; Terenig Terjanian
Journal:  Onco Targets Ther       Date:  2016-08-05       Impact factor: 4.147
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.